4,901 trials
Tumors Characterized by Genetic Abnormalities of ALK
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 Participants
Pharmacokinetics · Tolerability
Primary: Pharmacokinetics — 11.0 ng/dL
Diabetes Mellitus, Type 2
Primary: Number of Subjects With Drug Related Adverse Events — 7; 3; 4; 14 participants
Diabetes Mellitus, Type 2
Primary: Change in Clearance of Sodium, Potassium, Creatinine, Magnesium, Chloride,Calcium, Phosphate and Uric Acid From Baseline — -0.031; -0.055; -0.071; 0.143 ml/min
Stroke, Acute
Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants
Alcohol Abuse
Primary: Alcohol Use — 18; 14 participants
Schizophrenia · Autism
Primary: Lurasidone Primary Pharmacokinetic Parameters — 78; 140; 300; 115 ng.h/mL
Schizophrenia
Primary: Maximum Observed Plasma Concentration (Cmax) of Aripriprazole — 170; 136 ng/mL
Hypoxic Ischemic Encephalopathy
Primary: Feasibility Trial- the Olympic Cool Cap Will be Applied, Can the Delivered Cap Temperature be Less Than 12 Degrees Without Changing Rectal Temperature. — 2 participants
Healthy
Primary: Empa 25mg: Mean QTcN Change From Baseline Between 1 and 4 Hours After Dosing — 3.68; 4.27 ms
Healthy
Primary: Cmax Post Final Dose — 1944; 3807; 2293; 2777 ng/mL
Healthy
Primary: Empa: Area Under the Curve 0 to Infinity (AUC0-∞) — 5571.70; 5685.69 nmol*h/L
Type 1 Diabetes Mellitus
Primary: Early Insulin Exposure (%AUC[0-60]), Stage 1 — 20.99; 34.94; 32.83; 50.97 Percentage of AUC(0-360) — p=0.0009
B-cell Chronic Lymphocytic Leukemia · Small Lymphocytic Lymphoma
Primary: Incidence of Prolonged Hematologic Toxicity Started in Cycle 1 — 0; 0 Percentage of Participants
Upper Limb Nerve Block
Primary: Changes in Hemodynamic Parameters of Radial/Ulnar Artery From Baseline to 30min After Specific Nerve Block Followed by 30min After Brachial Plexus Block(Phase 1) — 40.9…